NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
4
Data completeness
6/8 — Strong
LASTACAFT (alcaftadine) by AbbVie is histamine h1 receptor antagonists [moa]. Approved for allergic conjunctivitis. First approved in 2010.
Drug data last refreshed 18h ago
Mechanism of Action
Histamine H1 Receptor Antagonists
Pharmacologic Class:
Histamine-1 Receptor Antagonist
Indications (1)
Clinical Trials (4)
Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Started Oct 2015
3,423 enrolled
Conjunctivitis, Allergic
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Started Nov 2012
157 enrolled
Conjunctivitis, Allergic
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Started Oct 2011
127 enrolled
Conjunctivitis, Allergic
A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
Started Apr 2011
25 enrolled
Allergic Conjunctivitis
Worked on LASTACAFT at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.